Pancreatic Cancer Research

ResearcherPeking University Cancer HospitalActive in the last 2 years

Chunyi Hao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1233-1689; OpenAlex author ID A5073849586, A5086047610, A5138018088. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 0, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers, 1 trial · 2026: 3 papers

Papers 26

  1. MICLEAR: Intelligent molecular cytology for intraoperative margin assessment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.media.2026.104181↗
  2. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  3. Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic Cancer. Co-author DOI 10.21873/cdp.10560↗
  4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  5. Core-fucosylated glycoproteins as biomarkers for diagnosing pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ijbiomac.2025.146774↗
  6. Noggin Promotes Cell Proliferation Through Up-regulating EGFR/HER2 in Pancreatic Cancer Cells. Co-author DOI 10.21873/cgp.20522↗
  7. Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic … Co-author DOI 10.7150/ijbs.108618↗
  8. EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer. Co-author DOI 10.1038/s41598-024-81485-w↗
  9. Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer. Co-author DOI 10.3390/cancers16162893↗
  10. Identification of the γ-glutamyl cycle as a novel therapeutic target and 5-oxoproline as a new biomarker for diagnosing pancreatic cancer. Last author DOI 10.1080/07853890.2023.2242247↗
  11. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630↗
  12. Establishment of a multi-parameters MRI model for predicting small lymph nodes metastases (<10 mm) in patients with resected pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00261-021-03347-7↗
  13. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  14. Expression of Death Associated Proteins DAP1 and DAP3 in Human Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15010↗
  15. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. Co-author DOI 10.3892/ijo.2021.5214↗
  16. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Co-author PMID 35018233↗
  17. Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.lfs.2020.118302↗
  18. Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Co-author DOI 10.1016/j.xphs.2019.10.035↗
  19. Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2020.618215↗
  20. N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. Co-author DOI 10.1016/j.taap.2019.114789↗
  21. T cell receptor β-chain repertoire analysis of tumor-infiltrating lymphocytes in pancreatic cancer. Last author DOI 10.1111/cas.13877↗
  22. Establishment of pancreatic cancer patient-derived xenograft models and comparison of the differences among the generations. Last author PMID 31217882↗
  23. Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.13950↗
  24. Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression. Co-author DOI 10.3892/ijo.2017.3953↗
  25. Suppression of CD26 inhibits growth and metastasis of pancreatic cancer. Last author DOI 10.1007/s13277-016-5315-4↗
  26. IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy. Co-author PMID 26977011↗

Trials 1

  1. Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Principal investigator NCT07277452↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen G. Jiang · 8 shared papers, 2016–2025 · strength 1.20
  2. Jianhui Wu · 6 shared papers, 2019–2026 · strength 1.14
  3. Kuirong Jiang · 1 shared paper, 1 shared trial, 2025–2026 · strength 1.03
  4. Bilal A. Al-Sarireh · 4 shared papers, 2017–2026 · strength 0.69
  5. Lin Ye · 2 shared papers, 2025–2026 · strength 0.62
  6. Lin Ye · 5 shared papers, 2016–2024 · strength 0.57
  7. Ziqian Fang · 2 shared papers, 2024–2026 · strength 0.52
  8. Shukui Qin · 2 shared papers, 2023–2026 · strength 0.36
  9. Shuhua Yue · 1 shared paper, 2026 · strength 0.36
  10. Tinghe Fang · 1 shared paper, 2026 · strength 0.36
  11. Laijian Sui · 2 shared papers, 2021–2024 · strength 0.34
  12. Jiujie Cui · 2 shared papers, 2022–2026 · strength 0.32
  13. Guanghai Dai · 2 shared papers, 2022–2026 · strength 0.32
  14. Jiafu Ji · 3 shared papers, 2016–2021 · strength 0.30
  15. Weijia Wang · 2 shared papers, 2020–2023 · strength 0.30
  16. Ye Yao · 3 shared papers, 2019–2020 · strength 0.30
  17. Tianyan Zhou · 3 shared papers, 2019–2020 · strength 0.30
  18. Hong Su · 3 shared papers, 2019–2020 · strength 0.30
  19. Qingyu Yao · 3 shared papers, 2019–2020 · strength 0.30
  20. Wantao Ying · 1 shared paper, 2025 · strength 0.28
  21. Ming Liu · 1 shared paper, 2025 · strength 0.28
  22. Xinyu Zhao · 1 shared paper, 2025 · strength 0.28
  23. Yiming Yang · 2 shared papers, 2021 · strength 0.28
  24. Min Zhao · 2 shared papers, 2017–2023 · strength 0.26
  25. Dao-Ning Liu · 2 shared papers, 2017–2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.